Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 2
2013 3
2014 7
2015 12
2016 18
2017 19
2018 26
2019 31
2020 52
2021 41
2022 44
2023 40
2024 50
2025 55
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

351 results

Results by year

Filters applied: . Clear all
Page 1
Defining the Role and Competencies of the Medical Oncologist in Diagnostic and Therapeutic Care Pathways: Consensus Recommendations from the Italian Association of Medical Oncology (AIOM).
Berardi R, Rossi F, Tarantino V, De Tursi M, Dinota A, Di Pinto G, Bianco R, Leonardi F, Bearz A, Fabi A, Pastorino A, Nolè F, Alessandroni P, Carrozza F, Buffoni L, Latiano T, Farci D, Spada M, Bengala C, Kinspergher S, Gunnellini M, Brunello A, Tucci M, Pietrantonio F, De Giorgi U, Incorvaia L, Micallo G, Russo A, Chiari R, Lambertini M, Curigliano G, Cinieri S, Silvestris N, Perrone F, Di Maio M, Papa R. Berardi R, et al. Among authors: lambertini m. J Cancer Policy. 2026 Jan 12:100701. doi: 10.1016/j.jcpo.2026.100701. Online ahead of print. J Cancer Policy. 2026. PMID: 41534717
Concomitant radiation therapy and trastuzumab deruxtecan in metastatic breast cancer: feasibility, safety, and outcomes from a real-life multicentre international cohort.
Visani L, Ratosa I, Bartsch R, Linderholm B, Griguolo G, Saieva C, Becherini C, Valzano M, Salvestrini V, Starzer AM, Kus P, Bertini N, Rampini A, Mattioli C, Ribnikar D, Nori Cucchiari J, Orzalesi L, Bianchi S, Lambertini M, Guarneri V, Livi L, Meattini I. Visani L, et al. Among authors: lambertini m. Breast. 2026 Jan 2;85:104691. doi: 10.1016/j.breast.2026.104691. Online ahead of print. Breast. 2026. PMID: 41496431 Free article.
Real-world effectiveness of PARP inhibitors after CDK4/6 inhibitor therapy in BRCA-mutated HR-positive/HER2-negative advanced breast cancer.
Zattarin E, Marra A, Palazzo A, Griguolo G, Vernieri C, Etessami J, Pontolillo L, Landa G, Daneri A, De Monte M, Cuoghi Costantini R, Tenedini E, Ponzoni O, Razeti MG, Sposetti C, Barbieri E, Manni M, Caggia F, Cortesi L, Curigliano G, Bria E, Dominici M, Guarneri V, Lambertini M, Toss A. Zattarin E, et al. Among authors: lambertini m. NPJ Breast Cancer. 2025 Dec 13;11(1):145. doi: 10.1038/s41523-025-00859-z. NPJ Breast Cancer. 2025. PMID: 41390667 Free PMC article.
Spatial multiomics of the breast tumour microenvironment: State of the field, advancements and clinical implementation promises.
Stylianakis D, Benjamin HA, Martella S, De Silva P, Stylianakis I, Denaro N, Leoni VP, Atzori L, Scartozzi M, Lambertini M, Solinas C, Willard-Gallo K. Stylianakis D, et al. Among authors: lambertini m. Crit Rev Oncol Hematol. 2025 Dec 11;218:105082. doi: 10.1016/j.critrevonc.2025.105082. Online ahead of print. Crit Rev Oncol Hematol. 2025. PMID: 41389952 Review.
Adjuvant ovarian function suppression and aromatase inhibitors in premenopausal patients with hormone receptor and HER2 positive breast cancer, by timing of chemotherapy and trastuzumab and response to neoadjuvant therapy.
Shai A, Wildiers H, Venieri C, Pogoda K, Linderholm B, Lambertini M, Matos L, De Maio D'Esposito E, Hajjaji N, Matos E, González Cortijo L, Fotia G, Fortuna A, Sella T, Gouveia H, Rosset L, Constantinidou A, Angeli E, Cicin I, Tjan-Heijnen V, Ruyssers N, Demasure S, Abu Remilah A, Huygh G, Paluch-Shimon S, Chiappe E, Shirron N, Neven P, Artac M, Kilictas B, Baranseh J, Vicente-Rubio E, Atci M, Amato O, van Duijnhoven F. Shai A, et al. Among authors: lambertini m. Breast. 2025 Dec 6:104669. doi: 10.1016/j.breast.2025.104669. Online ahead of print. Breast. 2025. PMID: 41387082 Free article.
The role of body mass index at diagnosis in patients with inflammatory breast cancer.
Borremans K, Nguyen HL, De Schepper M, Lerebours F, Vion R, Clatot F, Berghian A, Maetens M, Isnaldi E, Molinelli C, Lambertini M, Grillo F, Zoppoli G, Dirix L, Punie K, Wildiers H, Smeets A, Nevelsteen I, Neven P, Vincent-Salomon A, Larsimont D, Duhem C, Viens P, Bertucci F, Biganzoli E, Vermeulen P, Floris G, Richard F, Desmedt C. Borremans K, et al. Among authors: lambertini m. Breast. 2025 Dec;84:104599. doi: 10.1016/j.breast.2025.104599. Epub 2025 Oct 12. Breast. 2025. PMID: 41109066 Free PMC article.
Brain imaging screening in metastatic breast cancer: patients' and physicians' perspectives.
Matos L, van Ramshorst M, Müller V, Agostinetto E, Linn S, Lambertini M, Dieras V, le Du F, Braga S, Criscitiello C, Jerzak KJ, Morgan G, Brucker S, von Kroge P, Haidinger R, Rodríguez Recio G, Schumacher-Wulf E, Fontes Sousa M, Schettini F, Laakmann E. Matos L, et al. Among authors: lambertini m. Breast. 2025 Dec;84:104558. doi: 10.1016/j.breast.2025.104558. Epub 2025 Aug 12. Breast. 2025. PMID: 40849221 Free PMC article.
Efficacy and safety of systemic therapies following progression on CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer: a systematic review and network meta-analysis.
Buonaiuto R, Fordellone M, Caltavituro A, Cataldo ML, Criscitiello C, Dieci MV, Lambertini M, Botticelli A, Giuliano M, Giordano A, Mangiacotti F, Grieco A, Longobardi A, Caputo R, Pagliuca M, Vernieri C, Malorni L, Gerratana L, Arpino G, Chiodini P, De Laurentiis M, De Angelis C. Buonaiuto R, et al. Among authors: lambertini m. EClinicalMedicine. 2025 Sep 30;89:103535. doi: 10.1016/j.eclinm.2025.103535. eCollection 2025 Nov. EClinicalMedicine. 2025. PMID: 41079023 Free PMC article.
Comprehensive analysis of BRCA1/2 mutations, "BRCAness" and PARP inhibitors in melanoma.
Stylianakis D, Stylianakis I, Benjamin HA, Martella S, Tziotis A, Pellegrino B, De Silva P, Giannakis M, Perrone F, Lambertini M, Solinas C, Denaro N. Stylianakis D, et al. Among authors: lambertini m. Crit Rev Oncol Hematol. 2025 Nov;215:104962. doi: 10.1016/j.critrevonc.2025.104962. Epub 2025 Sep 20. Crit Rev Oncol Hematol. 2025. PMID: 40983306 Review.
351 results